论文部分内容阅读
目的探讨鼻咽癌(NPC)患者治疗前后血清血管内皮生长因子(VEGF)水平的变化及其临床意义。方法采用酶联免疫吸附试验(ELISA)对65例NPC患者在治疗前、治疗结束后1个月和治疗后出现局部复发或远处转移者,50例头颈部良性病变患者及50名正常人血清中VEGF水平进行检测。结果NPC治疗前组和治疗后复发组患者的血清VEGF水平明显高于头颈部良性病变组和正常对照组(P<0.01),与NPC治疗前比较,治疗后患者的血清VEGF水平明显下降(P<0.01),而治疗后复发组明显上升(P<0.01);临床Ⅲ~Ⅳ期NPC患者治疗前血清VEGF水平明显高于临床Ⅰ~Ⅱ期患者(P<0.01)。结论血清VEGF水平可作为NPC患者治疗前后病情监测及预后判断的一个新的检测指标。
Objective To investigate the changes of serum vascular endothelial growth factor (VEGF) levels in patients with nasopharyngeal carcinoma (NPC) and their clinical significance. Methods 65 patients with NPC were treated with enzyme-linked immunosorbent assay (ELISA) before treatment, one month after treatment and local recurrence or distant metastasis after treatment, 50 patients with benign head and neck disease and 50 normal subjects Serum VEGF levels were tested. Results The serum level of VEGF in NPC patients before and after treatment was significantly higher than that in benign lesions of head and neck and normal controls (P <0.01). Compared with NPC before treatment, serum VEGF level decreased significantly P <0.01), and the recurrence group after treatment was significantly increased (P <0.01). The serum VEGF level in patients with stage Ⅲ ~ Ⅳ NPC before treatment was significantly higher than that in stage Ⅰ ~ Ⅱ patients (P <0.01). Conclusion Serum VEGF levels can be used as a new detection index of NPC patients before and after treatment monitoring and prognosis.